colorectal cancer
Conditions
Interventions
Total:CPT-11, 5-Fu
Sponsors
Henan cancer hospital affiliated to Zhengzhou university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. colorectal cancer was histologically confirmed; 2. aged between 18 to 70years; 3. Disease evaluated according to RESCIST standard, the size >=1cm in CT/MRI or the size >=2cm by physical examination; 4. locally advanced (no operation or not totally resection R1/R2) colotectal cancer; metastatic or relapsed colorectal cancer; 5. FOLFIRI as first-line therapy, an anti-cancer targeting durg (such as cetuximab and (Bevacizumab) permitted and the palliative radiotherapy besides pelvis permitted; 6. no pregnant; 7. KPS>=60% or ECOG <=2; 8. written informed consent; 9. impared liver and renal function rectified to standard level.
Exclusion criteria
Exclusion criteria: 1. total bilirubin more than 3 times upper limit; creatinine more than 1.5 times upper limit; AST or ALT more than 2. 5 times upper limit without liver metastasis; AST or ALT more than 5 times upper limit with liver metastasis; 2. symptomatic brain metastasis; 3. severe marrow failure not rectified; 4. psychosis not easily controlled; 5. pregnant or lactation; 6. secondary cancer; 7. severe systemic disease: unstable angina, myocardial infarction, severe brain hemorrhage or cerbral infarction within 3 months; 8. chronic enteritis and CPT-11 not suitable to use; 9. bowel obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SNP associated with the effects/side effects of CPT-11, 5-Fu;diarrhea neutropenia cytopenia (III/IV) TTF;TIP30 promoter methylation;ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| SNP associated with prognose; | — |
Countries
China
Contacts
Public ContactLuo Suxia
Outcome results
None listed